Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xilio Therapeutics (XLO)
NASDAQ:XLO
XLO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $1.93
Previous CloseN/A
Volume162.24K
Average Volume (3M)7.20M
Market Cap
$48.50M
Enterprise Value-$2.85M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.79
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding45,756,040
10 Day Avg. Volume20,828,774
30 Day Avg. Volume7,198,080
Standard Deviation0.24
R-Squared0.00289
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.13
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.50
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$4.50Price Target Upside324.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Xilio Therapeutics News
PremiumCompany Announcements
Xilio Therapeutics Partners with AbbVie for Immunotherapy Expansion
PremiumCompany Announcements
Xilio Therapeutics Advances with Phase 2 Trial Data
---
Bulls Say, Bears Say
Bulls Say
CollaborationThe collaboration agreement with AbbVie further validates Xilio's capabilities and notably extends the cash runway.
Financial StabilityCurrent cash supports operations through 2Q25, providing financial stability for continued development.
Innovative TechnologyXilio's T-cell engager platform is differentiated by its masking technology, which is believed to be best in class at avoiding activation in the presence of healthy cells while increasing engagement with tumor cells.
Bears Say
Benchmark ChallengesXilio views the bar for success as an ORR of at least ~15% in patients without liver metastases, which is a relatively achievable benchmark.
Clinical TrialsInitial results from the Ph1C combo study of XTX101 being presented at SITC as a late breaker indicated potential signs of activity in a challenging patient population.
Patient EnrollmentThe company continues to enroll patients in the monotherapy dose escalation study at DL4 (60 ug/kg Q6W following a 15 ug/kg priming dose) and no DLTs have been observed.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XLO FAQ
What was Xilio Therapeutics’s price range in the past 12 months?
Xilio Therapeutics lowest stock price was $0.53 and its highest was $1.93 in the past 12 months.
What is Xilio Therapeutics’s market cap?
Xilio Therapeutics’s market cap is $48.50M.
When is Xilio Therapeutics’s upcoming earnings report date?
Xilio Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 74 days.
How were Xilio Therapeutics’s earnings last quarter?
Xilio Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.247 by $0.027.
Is Xilio Therapeutics overvalued?
According to Wall Street analysts Xilio Therapeutics’s price is currently Undervalued.
Does Xilio Therapeutics pay dividends?
Xilio Therapeutics does not currently pay dividends.
What is Xilio Therapeutics’s EPS estimate?
Xilio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xilio Therapeutics have?
Xilio Therapeutics has 45,756,040 shares outstanding.
What happened to Xilio Therapeutics’s price movement after its last earnings report?
Xilio Therapeutics reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.247. Following the earnings report the stock price went down -19.38%.
Which hedge fund is a major shareholder of Xilio Therapeutics?
Currently, no hedge funds are holding shares in XLO
---
Xilio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (324.53% Upside)
$4.50 (324.53% Upside)
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 40.2%
Last 30 Days ▲ 40.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
92.37%
12-Months-Change
Fundamentals
Return on Equity
-170.96%
Trailing 12-Months
Asset Growth
-4.09%
Trailing 12-Months
Company Description
Xilio Therapeutics
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer.
---
XLO Stock 12 Month Forecast
Average Price Target
$4.50
▲(324.53% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Immatics
―
ALX Oncology Holdings
―
Tango Therapeutics
―
Foghorn Therapeutics
―
Best Analysts Covering XLO
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-47.82%
reiterated a buy rating 10 days ago
Copying Michael Ulz's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -47.82% per trade.
---